Latest & greatest articles for Sibutramine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Sibutramine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Sibutramine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Sibutramine

21. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. Full Text available with Trip Pro

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. Adolescent obesity is becoming a national public health problem. Weight-loss medications including sibutramine facilitate weight control in adults and could be used with obese adolescents in combination with behavior therapy (BT).To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program.Randomized (...) , double-blind, placebo-controlled trial consisting of 82 adolescents aged 13 to 17 years with a body mass index (BMI) of 32 to 44 conducted from March 1999 to August 2002 at a university-based clinic for 6 months, followed by open-label treatment during months 7 to 12.For the first 6 months, participants received either BT and sibutramine or BT and placebo. From months 7 to 12, all participants received sibutramine in open-label treatment.Percentage change in BMI; systolic and diastolic blood pressure

2003 JAMA Controlled trial quality: predicted high

22. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment

The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G Authors' objectives To assess systematically the clinical effectiveness and cost (...) - effectiveness of sibutramine in the management of obesity. Searching Nineteen electronic databases were searched from inception to June 2000. These databases included MEDLINE, BIOSIS Previews, EMBASE, CINAHL and other topic-specific databases and citation indices. An extensive search strategy was reported in the appendices of the report. The authors also carried out Internet searches, checked the bibliographies of included papers for additional relevant studies, and received a submission of evidence from

2002 DARE.

23. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment

The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technology Assessment 2002; 6(6): 1-97 Authors' objectives This review aims to assess systematically the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity. Authors

2002 Health Technology Assessment (HTA) Database.

24. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. (Abstract)

Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Sibutramine is a tertiary amine that has been shown to induce dose-dependent weight loss and to enhance the effects of a low-calorie diet for up to a year. We did a randomised, double-blind trial to assess the usefulness of sibutramine in maintaining substantial weight loss over 2 years.Eight European centres recruited 605 obese patients (...) (body-mass index 30-45 kg/m2) for a 6-month period of weight loss with sibutramine (10 mg/day) and an individualised 600 kcal/day deficit programme based on measured resting metabolic rates. 467 (77%) patients with more than 5% weight loss were then randomly assigned 10 mg/day sibutramine (n=352) or placebo (n=115) for a further 18 months. Sibutramine was increased up to 20 mg/day if weight regain occurred. The primary outcome measure was the number of patients at year 2 maintaining at least 80

2001 Lancet Controlled trial quality: predicted high

25. Long-term weight loss with sibutramine: a randomized controlled trial. (Abstract)

Long-term weight loss with sibutramine: a randomized controlled trial. Treatment of obesity requires long-term therapy, which can be hampered by difficulties in achieving patient compliance. The effectiveness of sibutramine hydrochloride in treating obesity has been shown in randomized controlled trials.To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons.Randomized, double-blind, parallel-group placebo (...) -controlled trial from April 1997 to September 1998.One hundred eight private practices and 3 outpatient departments of university hospitals in Germany.A total of 1102 obese adults (body mass index, 30-40 kg/m(2)) entered the 4-week open-label run-in period with 15 mg/d of sibutramine, 1001 of whom had weight loss of at least 2% or 2 kg were randomized into the 44-week randomized treatment period.Patients were randomly assigned to receive 15 mg/d of sibutramine continuously throughout weeks 1-48 (n = 405

2001 JAMA Controlled trial quality: predicted high

26. Guidance on the use of sibutramine for the treatment of obesity in adults

Guidance on the use of sibutramine for the treatment of obesity in adults Guidance on the use of sibutramine for the treatment of obesity in adults Guidance on the use of sibutramine for the treatment of obesity in adults National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence (...) . Guidance on the use of sibutramine for the treatment of obesity in adults. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 31. 2001 Authors' objectives To provide guidance on the use of sibutramine for the treatment of obesity in adults. Authors' conclusions Guidance 1.1 Sibutramine should be prescribed only as part of an overall treatment plan for management of nutritional obesity in people aged 18-65 years who meet one of the following criteria: 1.1.1 a body

2001 Health Technology Assessment (HTA) Database.

27. Sibutramine: a review of its contribution to the management of obesity

Sibutramine: a review of its contribution to the management of obesity Sibutramine: a review of its contribution to the management of obesity Sibutramine: a review of its contribution to the management of obesity McNeely W, Goa K L Authors' objectives To review the contribution of sibutramine to the management of obesity. Searching Medical literature published in any language since 1966 identified using AdisBase (a proprietary database of Adis International, Auckland, New Zealand), MEDLINE (...) and EMBASE. Search terms used on all databases were 'sibutramine' and 'obesity'. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Study selection Study designs of evaluations included in the review Study designs reported in the review include double-blind, randomised controlled trials (RCTs). When available, large, well controlled trials

1998 DARE.